Abstract
e13004 Background: CTO is an oral inhibitor of non-voltage-dependent calcium signaling, which modulates several pathways (EGFR, MEK, RAS, HDAC, HSP90, WNT/B-catenin, Akt, ERK, VEGF, Bcr-Abl). We po...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have